MIST News and Press, Milestone Pharmaceuticals Inc. From 08/10/22

Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q2 GAAP EPS of -$0.39 misses by $0.03 . cash, cash equivalents, and short-term investments of $86.2 million For further details see: Milestone Pharmaceuticals GAAP EPS of -$0.39 misses by $0.03

Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update Canada NewsWire -- Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate pri...

Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C., June 2, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commerc...

Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , May 17, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the d...

Milestone Pharmaceuticals press release (NASDAQ:MIST): Q1 GAAP EPS of -$0.33. As of March 31, 2022, Milestone had cash, cash equivalents, and short-term investments of $100.2M. For further details see: Milestone Pharmaceuticals GAAP EPS of -$0.33

Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - RAPID topline data readout remains on track for mid-second half 2022 - Results from NODE-302 study highlights etripamil safety an...

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT Canada NewsWire - Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other ...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Canada NewsWire MONTREAL and CHARLOTTE, N.C. , April 15, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused o...

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT Canada NewsWire Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler , MD and Sean Pokorney , MD Conference call and webcast o...

Milestone Pharmaceuticals press release (NASDAQ:MIST): Q4 GAAP EPS of -$0.40 misses by $0.04. As of December 31, 2021, cash, cash equivalents, and short-term investments of $114.1 million, compared to $142.3 million as of December 31, 2020, For further details see: Milestone Pharmaceuti...